Skip to main content
. 2023 Sep 13;6(9):e2329583. doi: 10.1001/jamanetworkopen.2023.29583

Figure 1. One-Way Sensitivity Analysis of Retention on Medications for Opioid Use Disorder.

Figure 1.

The figure shows the cost-effectiveness of treatment with transmucosal buprenorphine and treatment with extended-release buprenorphine strategies as the 6-month rate of retention is increased. The dotted line at the incremental cost-effectiveness ratio (ICER) of $100 000 represents a threshold of $100 000 per quality-adjusted life years (QALY) willingness-to-pay and the dotted line at $0 represents the lowest value at which any strategy is not dominated. Any dots shown between the 2 sets of dotted lines are considered to be cost-effective strategies.